A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

This is an open-label, multicenter study of oral TR-701 FA 200 mg once daily for 6 days for
the treatment of major cutaneous abscess or cellulitis/erysipelas in patients 18 years of age
or older. This study is designed to further characterize the safety profile and gather
additional lesion measurement data of TR-701 FA in patients with major cutaneous abscess or
cellulitis/erysipelas.

Inclusion Criteria:

- Male or female patients ≥ 18 years of age

- Suspected or documented gram-positive infection from baseline Gram stain or culture.

- Cellulitis/erysipelas or major cutaneous abscesses at Screening

Exclusion Criteria:

- Postsurgical or open wound infections

- Severe sepsis or septic shock

- Uncomplicated skin and skin structure infections such as furuncles, minor abscesses (<
75 cm2 or area of suppuration not surrounded by cellulitis/erythema), and impetiginous
lesions

- Infections associated with, or in close proximity to, a prosthetic device

- Known bacteremia or osteomyelitis at time of screening